Baxter’s Generic Anesthetic Prevails In Patent Dispute With Abbott Labs

Law360, New York (September 26, 2005, 12:00 AM EDT) -- Baxter Pharmaceuticals has won a court’s green light to begin marketing a generic version of the popular anesthetic Ultane after prevailing in a patent infringement lawsuit brought by drug originator Abbott Laboratories.

Abbott sued Baxter in March 2001, when the generic maker sought approval to manufacture sevoflurane, the active ingredient in Ultane. Baxter completed an Abbreviated New Drug Application with the U.S. Food and Drug Administration, declaring it was not infringing Abbott’s patent.

A year later, the U.S. District Court for the Northern District of Illinois...
To view the full article, register now.